MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological disorders, MN-221 for the treatment of acute exacerbations of asthma, and MN-001 for NASH. MN-166 is being developed in multiple indications, largely through investigator-sponsored trials and outside funding. MediciNova is engaged in strategic partnering and consortium funding discussions to support further development of its programs.
Companies To Watch
XXII 1.45 N/A CKPT 9.00 N/A CPHR 2.99 N/A CFRX 1.25 N/A CRBP 5.80 N/A DMPI 2.12 N/A DVAX 9.25 N/A FBIO 4.48 N/A KERX 7.06 N/A MTNB 1.24 N/A MDGN 5.57 N/A MNOV 5.22 N/A MTFB 7.59 N/A PRQR 5.15 N/A STML 9.75 N/A SYN 0.501 N/A TGTX 11.55 N/A THLD 0.50 N/A TNXP 3.90 N/A URGN 18.40 N/A VSTM 3.60 N/A ZIOP 5.65 N/A 2017-07-27 15:59